Investigational Drug Information for Apricitabine
✉ Email this page to a colleague
What is the development status for investigational drug Apricitabine?
Apricitabine is an investigational drug.
There have been 6 clinical trials for Apricitabine.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2008.
The most common disease conditions in clinical trials are HIV Infections, Infections, and Acquired Immunodeficiency Syndrome. The leading clinical trial sponsors are Avexa and [disabled in preview].
Summary for Apricitabine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 827 |
| WIPO Patent Applications | 495 |
| Japanese Patent Applications | 248 |
| Clinical Trial Progress | Phase 2 (2008-05-01) |
| Vendors | 35 |
Recent Clinical Trials for Apricitabine
| Title | Sponsor | Phase |
|---|---|---|
| A Long Term Safety Study of Apricitabine in HIV-infected Patients | Avexa | Phase 3 |
| Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection | Avexa | Phase 2/Phase 3 |
| A Long Term, Safety Study of Apricitabine in HIV-infected Subjects | Avexa | Phase 2 |
Clinical Trial Summary for Apricitabine
Top disease conditions for Apricitabine
Top clinical trial sponsors for Apricitabine
US Patents for Apricitabine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
